Impaired blood flow in acute kidney injury: Pathophysiology and potential efficacy of intrarenal vasodilator therapy

Current Opinion in Critical Care

Volumn 15, Issue 6, 2009, Pages 514-519

  Tumlin, James A ^a  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

Acute kidney injury; Benephit catheter; Fenoldopam; Intrarenal; Renal blood flow; Urine output; Vasodilator

Indexed keywords

ACETYLCYSTEINE; ANARITIDE; FENOLDOPAM MESILATE; NESIRITIDE; VASODILATOR AGENT;

CLINICAL TRIAL; DIALYSIS; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; KIDNEY INJURY; MORBIDITY; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; REVIEW;

CATHETERIZATION; FENOLDOPAM; HUMANS; KIDNEY FAILURE, ACUTE; RENAL CIRCULATION; VASODILATOR AGENTS;

EID: 74949109663     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0b013e328332f6f9     Document Type: Review

References (41)

1. Brezis M, Rosen S. Hypoxia of the renal medulla: its implication for disease. N Engl J Med 1995; 332:647-655.
2. Losonczy G, Bloch JF, Samsell L, et al. Impact of surgery on nitric oxide in rats: evidence for activation of inducible nitric oxide synthase. Kidney Int 1997; 51:1943-1949.
3. Nygren, A. Contrast media and regional renal blood flow: a study of the effects of inonic and nonionic monmeric and dimeric contrast media in the rat. Invest Radiol 1989; 24:125-135.
4. Schwartz D, Mendonca M, Schwartz I, et al. Inhibition of constitutive nitric oxide synthase (NOS) by nitric oxide generated by inducible NOS after lipopolysaccharide administration provokes renal dysfunction in rats. J Clin Invest 1997; 100:439-448.
5. Epstein FH, Veves A, Prasad P. Effect of diabetes on renal medullary oxygenation during water diuresis. Diabetes Care 2002; 25:575-578.
6. Molitoris BA, Sandoval R, Sutton TA. Endothelial injury and dysfunction in ischemic acute renal failure. Crit Care Med 2002; 30:S235-S240.
7. Solez K, Morel-Maroger L, Sraer JD. The morphology of 'acute tubular necrosis' in man: analysis of 57 renal biopsies and a comparison with the glycerol model. Medicine 1979; 58:362-376.
8. Ramaswamy D, Corrigan G, Polhemus C, et al. Maintenance and recovery stages of postischemic acute renal failure in humans. Am J Renal Physiol 2002; 282:F271-F280.
9. Conger J, Robinette J, Villar A, et al. Increased nitric oxide synthase activity despite lack of response to endothelium-dependent vasodilators in postischemic acute renal failure in rats. J Clin Invest 1995; 96:631-638.
10. Jerkic M, Vojvodic S, Lopez-Novoa JM. The mechanism of increased renal susceptibility to toxic substances in the elderly. Int Urol Nephrol 2001; 32:539-547.
11. Ruschitzka F, Shaw S, Gygi D, et al. Endothelin dysfunction in acute renal failure: role of circulating and tissue endothelin-1. J Am Soc Nephrol 1999; 10:953-962.
12. Conger JD, Schultz MF, Miller F, Robinette JB. Responses to hemorrahagic arterial pressure reduction in different ischemic renal failure models. Kidney Int 1994; 46:318-323.
13. Sutton TA, Fisher CJ, Molitoris BA. Microvascular injury and dysfunction during ischemic acute renal failure. Kidney Int 2002; 62:1539-1549.
14. Okusa MD, Linden J, MacDonald T, Huang L. Selective A2a adenosine receptor activation reduces ischemia-reperfusion injury in rat kidney. Am J Physiol Renal 1999; 277:F404-F412.
15. Kelly KJ, Williams WW, Colvin RB, et al. Intercellular adhesion molecule-1- deficient mice are protected against ischemic renal injury. J Clin Invest 1996; 97:1056-1063.
16. Molitoris BA, Marrs J. The role of cell adhesion molecules in ischemic acute renal failure. Am J Med 1999; 106:583-592.
17. Linas SL, Whittenburg D, Parsons PE, Repine JE. Mild renal ischemia activates primed neutrophiles to cause acute renal failure. Kidney Int 1992; 42:610-616.
18. Denton MD, Chertow GM, Brady HR. 'Renal-dose' dopamine for the treatment of acute renal failure: scientific rationale, experimental studies, and clinical trials. Kidney Int 1996; 49:4-14.
19. Tumlin JA, Finkel KW, Murray PT, et al. Fenoldopam mesylate in early acute tubular necrosis: a randomized, double-blind, placebo-controlled clinical trial. Am J Kidney Dis 2005; 46:26-34.
20. Allgren RL, Marbury TC, Rahman SN, et al. Anaritide in acute tubular necrosis. N Engl J Med 1997; 336:828-834.
21. Mentzer RM, Oz MC, Sladen RN, et al. Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery: the NAPA trial. J Am Coll Cardiol 2007; 49:716-726.
22. Hirschberg R, Kopple J, Lipsett P, et al. Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure. Kidney Int 1999; 55:2423-2432.
23. Lewis J, SalemMM, Chertow GM, et al. Atrial natriuretic factor in oliguric acute renal failure. Am 2000; 36:767-774.
24. Sward K, Valsson F, Odencrants P, et al. Recombinant human atrial natriuretic peptide in ischemic acute renal failure: a randomized placebo-controlled trial. Crit Care Med 2004; 32:1310-1315.
25. Mentzer RM, Oz MC, Sladen RN, et al. Renal dysfunction after myocardial revascularization: risk factors, adverse outcomes, and hospital resource utilization. Ann Intern Med 1998; 128:194-203.
26. Drager L, Andrade L, Barros JF, et al. Renal effects of N-acetylcysteine in patients at risk for contrast nephropathy: decrease in oxidant stress-mediated renal tubular injury. Nephrol Dial Transplant 2004; 19:1803-1807.
27. Wu H, Chen G, Wyburn KR, et al. TL4 activation mediates kidney ischemia/ reperfusion injury. J Clin Invest 2007; 117:2847-2859.
28. Webb JG, Pate GE, Humphries KH, et al. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. Am Heart J 2009; 148:422-429.
29. Singer I, Epstein M. Potential of dopamine A-1 agonists in the management of acute renal failure. Am J Kidney Dis 1998; 31:743-755.
30. Cheung PY, Barrington KJ. Renal dopamine receptors: mechanisms of action and developmental aspects. Cardiovasc Res 1996; 31:2-6.
31. Han G, Kryman JP, McMillin PJP, et al. A novel transduction mechanism mediating dopamine-induced vascular relaxation: opening of BKca channels by cyclic AMP-induced stimulation of the cyclic GMP-dependent protein kinase. J Cardiovasc Phamacol 1999; 34:619-627.
32. Kien ND, Moore PG, Jaffe RS. Cardiovascular function during induced hypotension by fenoldopam or sodium nitroprusside in anesthetized dogs. Anesth Analg 1992; 74:72-78.
33. Aravindan N, Samuels J, Riedel B, Shaw A. Fenoldopam improves corticomedullary oxygen delivery and attentuates angiogenesis gene expression in acute ischemic renal injury. Kidney Blood Press Res 2006; 29:165-174.
34. Mathur VS, Swan SK, Lambrecht LJ, et al. The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects. Crit Care Med 1999; 27:1832-1837.
35. O'Connell DP, Ragsdale NV, Boyd DG, et al. Differential human renal tubular responses to dopamine type-1 receptor stimulation are determined by blood pressure status. Hypertension 1997; 29:115-122.
36. Tumlin JA, Wang A, Mathur VS, et al. Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy. Am Heart J 2003; 143:894-903.
37. Bove T, Landoni G, Calabro MG, et al. Renoprotective action of fendoldopam in high risk patients undergoing cardiac surgery: a prospective, doubl-blind, randomized clinical trial. Circulation 2005; 111:3230-3235.
38. Landoni G, Biondi-Zoccai GGL, Marino G, et al. Fenoldopam reduces the need for renal replacement therapy and in-hospital death in cardiovascular surgery: a meta-analysis. Am J Kidney Dis 2008; 22:27-33.
39. Weisz G, Filby SJ, Cohen MG, et al. Safety and performance of targeted renal therapy: the Be-RITe! Registry. J Endovasc Ther 2009; 16:1-12.
40. Teirstein PS, Price MJ, Mathur VS, et al. Differential effects between intravenous and targeted renal delivery of fenoldopam on renal function and blood pressure in patients undergoing cardiac catheterization. Am J Cardiol 2006; 97:1076-1081.
41. Chen HH, Cataliotti A, Schirger JA, et al. Local renal delivery of a natriuretic peptide: a renal enhancing strategy for B-type natriuretic peptide in overt experimental heart failure. J Am Coll Cardiol 2009; 53:1302-1308.